You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically

Efficacy and safety of entrectinib▼ in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

Entrectinib▼ is a tyrosine kinase inihbitor approved globally for the treatment of NTRK fusion-positive solid tumours, based on the results of three phase 1/2 trials (ALKA-372-001; STARTRK-1; STARTRK-2). Updated results (enrolment cut-off: 31 Jul 2019; clinical cut-off 31 Aug 2020) are presented.

Browse more content from this congress

View additional content from this congress. Use the filters to refine your search.

Please validate reCAPTCHA.

Request received

Thank you! Please check your email to view the asset(s) you requested.

Continue browsing

You are Leaving Medically

Efficacy and safety of entrectinib▼ in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

Entrectinib▼ is a tyrosine kinase inihbitor approved globally for the treatment of NTRK fusion-positive solid tumours, based on the results of three phase 1/2 trials (ALKA-372-001; STARTRK-1; STARTRK-2). Updated results (enrolment cut-off: 31 Jul 2019; clinical cut-off 31 Aug 2020) are presented.

Request medical material

Browse more content from this congress

Request received